Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Understanding cancer therapies [[electronic resource] /] / Helen S.L. Chan
| Understanding cancer therapies [[electronic resource] /] / Helen S.L. Chan |
| Autore | Chan Helen S. L |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Jackson, : University Press of Mississippi, 2007 |
| Descrizione fisica | 1 online resource (150 p.) |
| Disciplina | 616.99/406 |
| Collana | Understanding health and sickness series |
| Soggetto topico | Cancer - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-283-01812-8
9786613018120 1-60473-951-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Overview on cancer therapies -- How cancer therapy is determined -- How chemotherapy works -- Surgical oncology -- Radiation therapy -- Biologic and other therapies -- Therapies for childhood cancer -- Therapies for cancer in adults -- Search for cures. |
| Record Nr. | UNINA-9910458589403321 |
Chan Helen S. L
|
||
| Jackson, : University Press of Mississippi, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Understanding cancer therapies [[electronic resource] /] / Helen S.L. Chan
| Understanding cancer therapies [[electronic resource] /] / Helen S.L. Chan |
| Autore | Chan Helen S. L |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Jackson, : University Press of Mississippi, 2007 |
| Descrizione fisica | 1 online resource (150 p.) |
| Disciplina | 616.99/406 |
| Collana | Understanding health and sickness series |
| Soggetto topico | Cancer - Treatment |
| ISBN |
1-283-01812-8
9786613018120 1-60473-951-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Overview on cancer therapies -- How cancer therapy is determined -- How chemotherapy works -- Surgical oncology -- Radiation therapy -- Biologic and other therapies -- Therapies for childhood cancer -- Therapies for cancer in adults -- Search for cures. |
| Record Nr. | UNINA-9910791681903321 |
|
Chan Helen S. L
|
||
| Jackson, : University Press of Mississippi, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Understanding cancer therapies [[electronic resource] /] / Helen S.L. Chan
| Understanding cancer therapies [[electronic resource] /] / Helen S.L. Chan |
| Autore | Chan Helen S. L |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Jackson, : University Press of Mississippi, 2007 |
| Descrizione fisica | 1 online resource (150 p.) |
| Disciplina | 616.99/406 |
| Collana | Understanding health and sickness series |
| Soggetto topico | Cancer - Treatment |
| ISBN |
1-283-01812-8
9786613018120 1-60473-951-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Overview on cancer therapies -- How cancer therapy is determined -- How chemotherapy works -- Surgical oncology -- Radiation therapy -- Biologic and other therapies -- Therapies for childhood cancer -- Therapies for cancer in adults -- Search for cures. |
| Record Nr. | UNINA-9910817791903321 |
|
Chan Helen S. L
|
||
| Jackson, : University Press of Mississippi, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Viral therapy of cancer [[electronic resource] /] / editors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha
| Viral therapy of cancer [[electronic resource] /] / editors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha |
| Pubbl/distr/stampa | Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 |
| Descrizione fisica | 1 online resource (426 p.) |
| Disciplina |
616.99/406
616.99406 |
| Altri autori (Persone) |
HarringtonKevin J. <1958->
PandhaHardev VileRichard G |
| Soggetto topico |
Viruses - Therapeutic use
Cancer - Treatment |
| ISBN |
1-282-35017-X
9786612350177 0-470-98579-8 0-470-98578-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Viral Therapy of Cancer; Contents; Foreword; Preface; Contributors; 1 Adenoviruses; 1.1 Introduction; 1.2 Viral structure and life cycle; 1.3 Adenoviral vectors; 1.4 Targeting adenoviral vectors; 1.5 Clinical applications of adenoviral gene therapy; 1.6 Adenoviral vectors for immunotherapy; 1.7 Adenoviral vectors for suicide gene therapy; 1.8 Adenoviral vectors for gene replacement therapy; 1.9 Oncolytic adenoviral therapy; 1.10 Adverse outcomes of adenoviral gene therapy; 1.11 Summary; References; 2 Application of HSV-1 vectors to the treatment of cancer; 2.1 Introduction
2.2 Basic biology of HSV2.3 Replication competent or oncolytic vectors; 2.4 Replication defective vectors; 2.5 Amplicons; 2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy; 2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy; 2.8 Summary and conclusions; Acknowledgements; References; 3 Adeno-associated virus; 3.1 Introduction; 3.2 Biology and life cycle of AAV; 3.3 AAV serotypes; 3.4 Production of recombinant AAV; 3.5 Gene therapy for cancer treatment; 3.6 Anti-oncogenic properties of AAV 3.7 Molecular chemotherapy studies with rAAV3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy; 3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses; 3.10 rAAV vectors can be used to initiate immune responses; 3.11 Altering AAV tropism for tumour-specific delivery; 3.12 Clinical trials involving rAAV; 3.13 Conclusion; Acknowledgements; References; 4 Retroviruses; 4.1 Introduction; 4.2 Structure of retroviral particles; 4.3 Retroviral genome; 4.4 Retroviral life cycle; 4.5 Retroviral vectors 4.6 Safety of retroviral vectors: insertional mutagenesis4.7 Gene therapy of X-linked SCID; 4.8 Retroviral cancer gene therapy; 4.9 Immunomodulatory approaches; 4.10 Conclusions; References; 5 Lentiviral vectors for cancer gene therapy; 5.1 Development of lentiviral vectors (LV); 5.2 Targeting of transgene expression; 5.3 Host immune responses to LV and their transgene; 5.4 Transgenesis; 5.5 Haematopoietic stem cell gene transfer; 5.6 Cancer treatment by LV; 5.7 Approved clinical trials using LV; 5.8 Conclusions; References; 6 Poxviruses as immunomodulatory cancer therapeutics 6.1 Introduction6.2 General features of poxvirus structure and biology; 6.3 Clinically applicable poxviruses; 6.4 Poxviruses as potential cancer therapeutics; 6.5 Clinical experience with poxviruses; 6.6 Conclusions; References; 7 Oncolytic herpes simplex viruses; 7.1 Introduction; 7.2 Herpes simplex virology; 7.3 Properties of HSV relevant to oncolytic virus therapy; 7.4 Mutations giving tumour-selective replication; 7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG); 7.6 Prodrug activation therapy and oncolytic HSV 7.7 Combination of oncolytic HSV with immunomodulatory gene expression |
| Record Nr. | UNINA-9910144698803321 |
| Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Viral therapy of cancer [[electronic resource] /] / editors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha
| Viral therapy of cancer [[electronic resource] /] / editors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha |
| Pubbl/distr/stampa | Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 |
| Descrizione fisica | 1 online resource (426 p.) |
| Disciplina |
616.99/406
616.99406 |
| Altri autori (Persone) |
HarringtonKevin J. <1958->
PandhaHardev VileRichard G |
| Soggetto topico |
Viruses - Therapeutic use
Cancer - Treatment |
| ISBN |
1-282-35017-X
9786612350177 0-470-98579-8 0-470-98578-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Viral Therapy of Cancer; Contents; Foreword; Preface; Contributors; 1 Adenoviruses; 1.1 Introduction; 1.2 Viral structure and life cycle; 1.3 Adenoviral vectors; 1.4 Targeting adenoviral vectors; 1.5 Clinical applications of adenoviral gene therapy; 1.6 Adenoviral vectors for immunotherapy; 1.7 Adenoviral vectors for suicide gene therapy; 1.8 Adenoviral vectors for gene replacement therapy; 1.9 Oncolytic adenoviral therapy; 1.10 Adverse outcomes of adenoviral gene therapy; 1.11 Summary; References; 2 Application of HSV-1 vectors to the treatment of cancer; 2.1 Introduction
2.2 Basic biology of HSV2.3 Replication competent or oncolytic vectors; 2.4 Replication defective vectors; 2.5 Amplicons; 2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy; 2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy; 2.8 Summary and conclusions; Acknowledgements; References; 3 Adeno-associated virus; 3.1 Introduction; 3.2 Biology and life cycle of AAV; 3.3 AAV serotypes; 3.4 Production of recombinant AAV; 3.5 Gene therapy for cancer treatment; 3.6 Anti-oncogenic properties of AAV 3.7 Molecular chemotherapy studies with rAAV3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy; 3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses; 3.10 rAAV vectors can be used to initiate immune responses; 3.11 Altering AAV tropism for tumour-specific delivery; 3.12 Clinical trials involving rAAV; 3.13 Conclusion; Acknowledgements; References; 4 Retroviruses; 4.1 Introduction; 4.2 Structure of retroviral particles; 4.3 Retroviral genome; 4.4 Retroviral life cycle; 4.5 Retroviral vectors 4.6 Safety of retroviral vectors: insertional mutagenesis4.7 Gene therapy of X-linked SCID; 4.8 Retroviral cancer gene therapy; 4.9 Immunomodulatory approaches; 4.10 Conclusions; References; 5 Lentiviral vectors for cancer gene therapy; 5.1 Development of lentiviral vectors (LV); 5.2 Targeting of transgene expression; 5.3 Host immune responses to LV and their transgene; 5.4 Transgenesis; 5.5 Haematopoietic stem cell gene transfer; 5.6 Cancer treatment by LV; 5.7 Approved clinical trials using LV; 5.8 Conclusions; References; 6 Poxviruses as immunomodulatory cancer therapeutics 6.1 Introduction6.2 General features of poxvirus structure and biology; 6.3 Clinically applicable poxviruses; 6.4 Poxviruses as potential cancer therapeutics; 6.5 Clinical experience with poxviruses; 6.6 Conclusions; References; 7 Oncolytic herpes simplex viruses; 7.1 Introduction; 7.2 Herpes simplex virology; 7.3 Properties of HSV relevant to oncolytic virus therapy; 7.4 Mutations giving tumour-selective replication; 7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG); 7.6 Prodrug activation therapy and oncolytic HSV 7.7 Combination of oncolytic HSV with immunomodulatory gene expression |
| Record Nr. | UNINA-9910830389603321 |
| Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Viral therapy of cancer [[electronic resource] /] / editors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha
| Viral therapy of cancer [[electronic resource] /] / editors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha |
| Pubbl/distr/stampa | Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 |
| Descrizione fisica | 1 online resource (426 p.) |
| Disciplina |
616.99/406
616.99406 |
| Altri autori (Persone) |
HarringtonKevin J. <1958->
PandhaHardev VileRichard G |
| Soggetto topico |
Viruses - Therapeutic use
Cancer - Treatment |
| ISBN |
1-282-35017-X
9786612350177 0-470-98579-8 0-470-98578-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Viral Therapy of Cancer; Contents; Foreword; Preface; Contributors; 1 Adenoviruses; 1.1 Introduction; 1.2 Viral structure and life cycle; 1.3 Adenoviral vectors; 1.4 Targeting adenoviral vectors; 1.5 Clinical applications of adenoviral gene therapy; 1.6 Adenoviral vectors for immunotherapy; 1.7 Adenoviral vectors for suicide gene therapy; 1.8 Adenoviral vectors for gene replacement therapy; 1.9 Oncolytic adenoviral therapy; 1.10 Adverse outcomes of adenoviral gene therapy; 1.11 Summary; References; 2 Application of HSV-1 vectors to the treatment of cancer; 2.1 Introduction
2.2 Basic biology of HSV2.3 Replication competent or oncolytic vectors; 2.4 Replication defective vectors; 2.5 Amplicons; 2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy; 2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy; 2.8 Summary and conclusions; Acknowledgements; References; 3 Adeno-associated virus; 3.1 Introduction; 3.2 Biology and life cycle of AAV; 3.3 AAV serotypes; 3.4 Production of recombinant AAV; 3.5 Gene therapy for cancer treatment; 3.6 Anti-oncogenic properties of AAV 3.7 Molecular chemotherapy studies with rAAV3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy; 3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses; 3.10 rAAV vectors can be used to initiate immune responses; 3.11 Altering AAV tropism for tumour-specific delivery; 3.12 Clinical trials involving rAAV; 3.13 Conclusion; Acknowledgements; References; 4 Retroviruses; 4.1 Introduction; 4.2 Structure of retroviral particles; 4.3 Retroviral genome; 4.4 Retroviral life cycle; 4.5 Retroviral vectors 4.6 Safety of retroviral vectors: insertional mutagenesis4.7 Gene therapy of X-linked SCID; 4.8 Retroviral cancer gene therapy; 4.9 Immunomodulatory approaches; 4.10 Conclusions; References; 5 Lentiviral vectors for cancer gene therapy; 5.1 Development of lentiviral vectors (LV); 5.2 Targeting of transgene expression; 5.3 Host immune responses to LV and their transgene; 5.4 Transgenesis; 5.5 Haematopoietic stem cell gene transfer; 5.6 Cancer treatment by LV; 5.7 Approved clinical trials using LV; 5.8 Conclusions; References; 6 Poxviruses as immunomodulatory cancer therapeutics 6.1 Introduction6.2 General features of poxvirus structure and biology; 6.3 Clinically applicable poxviruses; 6.4 Poxviruses as potential cancer therapeutics; 6.5 Clinical experience with poxviruses; 6.6 Conclusions; References; 7 Oncolytic herpes simplex viruses; 7.1 Introduction; 7.2 Herpes simplex virology; 7.3 Properties of HSV relevant to oncolytic virus therapy; 7.4 Mutations giving tumour-selective replication; 7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG); 7.6 Prodrug activation therapy and oncolytic HSV 7.7 Combination of oncolytic HSV with immunomodulatory gene expression |
| Record Nr. | UNINA-9910840787103321 |
| Chichester, England ; ; Hoboken, NJ, : John Wiley & Sons, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
